Search Results

You are looking at 1 - 6 of 6 items for

  • Author or Editor: Glenna E. Mauldin x
  • Refine by Access: All Content x
Clear All Modify Search

Abstract

Objective—To determine sensitivity and specificity of assays of D-dimer concentrations in dogs with disseminated intravascular coagulation (DIC) and healthy dogs and to compare these results with those of serum and plasma fibrin-fibrinogen degradation product (FDP) assays.

Animals—20 dogs with DIC and 30 healthy dogs.

Procedure—Semi-quantitative and quantitative D-dimer concentrations were determined by use of latex-agglutination and immunoturbidometry, respectively. Fibrin-fibrinogen degradation products were measured by use of latex-agglutination. A reference range for the immunoturbidometric D-dimer concentration assay was established; sensitivity and specificity of the assay were determined at 2 cutoff concentrations (0.30 µg/ml and 0.39 µg/ml).

Results—Reference range for the immunoturbidometric D-dimer concentration assay was 0.08 to 0.39 µg/ml; median concentrations were significantly higher in dogs with DIC than in healthy dogs. Latexagglutination D-dimer and serum and plasma FDP assays had similar sensitivity (85 to 100%) and specificity (90 to 100%); the immunoturbidometric assay had lower specificity (77%) at the 0.30 µg/ml cutoff and lower sensitivity (65%) at the 0.39 µg/ml cutoff. Sensitivity or specificity of the latex-agglutination D-dimer assay was not significantly improved when interpreted in series or parallel with FDP assays.

Conclusions and Clinical Relevance—Measurement of D-dimer concentrations by latex-agglutination appears to be a sensitive and specific ancillary test for DIC in dogs. Specificity of D-dimer concentrations in dogs with systemic disease other than DIC has not been determined, therefore FDP and D-dimer assays should be performed concurrently as supportive tests for the diagnosis of DIC in dogs. (Am J Vet Res 2000;61:393–398)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To evaluate the effect of diets enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on in vivo production of interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, prostaglandin E2 (PGE2), and platelet-activating factor (PAF) in dogs.

Animals—15 young healthy dogs.

Procedures—Dogs were randomly allocated to receive an isocaloric ration supplemented with sunflower oil (n = 5), fish oil (5), or fish oil plus vitamin E (5) for 12 weeks. At week 12, in vivo production of inflammatory mediators was evaluated in serum at multiple time points for 6 hours following stimulation with IV administration of lipopolysaccharide (LPS).

Results—Serum activity or concentration (area under the curve) of IL-1, IL-6, and PGE2 significantly increased after LPS injection in all groups but to a lesser extent in dogs receiving the fish oil diet, compared with results for dogs receiving the sunflower oil diet. Serum activity of TNF-α and PAF concentration also increased significantly after LPS injection in all groups but did not differ significantly among groups.

Conclusions and Clinical Relevance—A fish oil–enriched diet consisting of 1.75 g of EPA/kg of diet and 2.2 g of DHA/kg of diet (dry-matter basis) with an n-6:n-3 fatty acid ratio of 3.4:1 was associated with significant reductions in serum PGE2 concentrations and IL-1 and IL-6 activities. Results supported the use of EPA- and DHA-enriched diets as part of antiinflammatory treatments for dogs with chronic inflammatory diseases. Additional studies in affected dogs are warranted to further evaluate beneficial anti-inflammatory effects of EPA- and DHA-enriched diets.

Full access
in American Journal of Veterinary Research

Abstract

Objective—To determine nitrogen balance in clinically normal dogs receiving parenteral nutrition solutions.

Animals—8 clinically normal female Beagles.

Procedure—Dogs were randomly assigned to receive 4 treatments in random order. Treatment A consisted of IV administration of nonlactated Ringer's solution. Treatments B, C, and D consisted of IV administration of isocaloric parenteral solutions containing 0, 1.36, and 2.04 g of amino acids/kg of body weight/d, respectively, for 7 consecutive days. Urine and feces were collected on days 5, 6, and 7 of each treatment period, and Kjeldahl analysis was used to determine nitrogen balance.

Results—Mean nitrogen balance was negative with treatments A and B but was not significantly different from 0 with treatments C and D. Dogs had the lowest nitrogen balance values and lost the most weight while receiving treatment A. Dogs were able to conserve protein and had higher nitrogen balance values when receiving treatment B, compared with treatment A. Dogs lost the least amount of weight while receiving treatment D. Regression analysis indicated that an IV amino acid intake of 2.32 g/kg/d (95% confidence interval, 2.00 to 2.81 g/kg/d), as supplied by the commercial product used in this study, would result in zero nitrogen balance in clinically normal dogs.

Conclusions and Clinical Relevance—Results suggest that IV amino acid requirement of clinically normal dogs is approximately 2.3 g/kg/d. ( Am J Vet Res 2001;62:912–920)

Full access
in American Journal of Veterinary Research

Abstract

Objective—To evaluate factors associated with survival in dogs with nasal carcinomas that did not receive treatment or received only palliative treatment.

Design—Retrospective case series.

Animals—139 dogs with histologically confirmed nasal carcinomas.

Procedures—Medical records, computed tomography images, and biopsy specimens of nasal carcinomas were reviewed. Only dogs that were not treated with radiation, surgery, chemotherapy, or immunotherapy and that survived ≥ 7 days from the date of diagnosis were included. The Kaplan-Meier method was used to estimate survival time. Factors potentially associated with survival were compared by use of log-rank and Wilcoxon rank sum tests. Multivariable survival analysis was performed by use of the Cox proportional hazards regression model.

Results—Overall median survival time was 95 days (95% confidence interval [CI], 73 to 113 days; range, 7 to 1,114 days). In dogs with epistaxis, the hazard of dying was 2.3 times that of dogs that did not have epistaxis. Median survival time of 107 dogs with epistaxis was 88 days (95% CI, 65 to 106 days) and that of 32 dogs without epistaxis was 224 days (95% CI, 54 to 467 days).

Conclusions and Clinical Relevance—The prognosis of dogs with untreated nasal carcinomas is poor. Treatment strategies to improve outcome should be pursued.

Full access
in Journal of the American Veterinary Medical Association

Objective

To evaluate a group of cats with malignant colonic neoplasia and to identify factors related to survival time.

Design

Retrospective study.

Animals

46 cats with malignant colonic neoplasia.

Procedure

Information on signalment, diagnostic findings, histopathologic diagnosis, surgical procedure performed, identification of nodal metastasis at surgery, type of chemotherapy administered, and survival time was obtained from the medical record of each cat. A diagnosis of malignant colonic neoplasia had been established by histologic examination of endoscopic biopsy specimens (3 cats), biopsy specimens obtained during laparotomy (38), or necropsy specimens (5).

Results

Mean age of cats was 12.5 years (range, 6 to 18 years). Ultrasonography was useful 84% of the time in localizing the mass to the intestine. Three cats had endoscopic biopsy, 9 had incisional biopsy, 21 had mass resection, and 8 had subtotal colectomy performed. Histopathologic diagnoses included adenocarcinoma (21 cats), lymphoma (19), mast cell tumor (4), and neuroendocrine carcinoma (2).

Clinical Implications

Obtaining clean margins at surgery seems to increase survival time in cats with malignant colonic neoplasia. Metastasis at the time of surgery decreases survival time. Data from this study indicate that the survival time of certain cats with colonic lymphoma may not be affected by chemotherapy. Cats with an unidentified colonic mass should receive a subtotal colectomy to increase survival time. Cats with colonic adenocarcinoma should receive a subtotal colectomy with consideration of doxorubicin administration to increase survival time. (J Am Vet Med Assoc 1997; 211:878–881)

Free access
in Journal of the American Veterinary Medical Association

Abstract

Objective—To determine the prognostic factors for survival and tumor recurrence in dogs with cutaneous mast cell tumors (MCTs) in the perineal and inguinal regions treated surgically with or without adjunctive radiation therapy, chemotherapy, or both.

Design—Retrospective study.

Animals—68 dogs.

Procedure—Medical records of dogs with histologically confirmed MCTs in the perineal region, inguinal region, or both treated surgically with or without adjunctive radiation therapy, chemotherapy, or both were reviewed.

Results—Mean tumor-free interval was 1,635 days (median not reached), and 1- and 2-year tumor-free rates were 79% and 71%, respectively. Median survival time was 1,111 days (mean, 1,223 days), and 1- and 2-year survival rates were 79% and 61%, respectively. Factors that negatively influenced survival time were age at diagnosis, tumor recurrence, and treatment with lomustine.

Conclusions and Clinical Relevance—Results indicated that dogs with MCTs in the inguinal and perineal regions, if appropriately treated, may have survival times and tumor-free intervals similar to dogs with MCTs in other locations. ( J Am Vet Med Assoc 2004;225:401–408)

Full access
in Journal of the American Veterinary Medical Association